Literature DB >> 2828920

Expression of HLA-DR antigen in human class II mutant B-cell lines by double infection with retrovirus vectors.

Z Yang1, A J Korman, J Cooper, D Pious, R S Accolla, R C Mulligan, J L Strominger.   

Abstract

A new retrovirus vector containing the gene for hygromycin B resistance (hyg) as a selectable marker under the control of an internal simian virus 40 promoter was constructed. It was used, together with an analogous previously described vector, DO1, which contains the gene for G418 resistance, to introduce and express the genes for the two chains of a human class II major histocompatibility complex antigen in NIH 3T3 cells. In addition, these vectors were used to express DR antigens in two human mutant B-lymphoblastoid cell lines, one of which was deleted for both alleles of the DR alpha gene and the other of which expressed no class II antigens because of a genetic defect in a putative trans-acting regulatory factor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2828920      PMCID: PMC368060          DOI: 10.1128/mcb.7.11.3923-3928.1987

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  18 in total

1.  Analysis of the DR beta chains from two DRw6 cell lines (WT46 and WT52): recombination in vivo may have generated new haplotypes.

Authors:  P J Knudsen; J McLean; J L Strominger
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

2.  Expression of human class II major histocompatibility complex antigens using retrovirus vectors.

Authors:  A J Korman; J D Frantz; J L Strominger; R C Mulligan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

3.  A monoclonal antibody that recognizes the alpha chain of HLA-DR antigens.

Authors:  P J Knudsen; J L Strominger
Journal:  Hum Immunol       Date:  1986-02       Impact factor: 2.850

4.  Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.

Authors:  R Mann; R C Mulligan; D Baltimore
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

5.  Recognition of HLA-A2 and -B7 antigens by cloned cytotoxic T lymphocytes after gene transfer into human and monkey, but not mouse, cells.

Authors:  J A Barbosa; S J Mentzer; G Minowada; J L Strominger; S J Burakoff; P A Biro
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

6.  A vector that replicates as a plasmid and can be efficiently selected in B-lymphoblasts transformed by Epstein-Barr virus.

Authors:  B Sugden; K Marsh; J Yates
Journal:  Mol Cell Biol       Date:  1985-02       Impact factor: 4.272

7.  Insertion mutagenesis of embryonal carcinoma cells by retroviruses.

Authors:  W King; M D Patel; L I Lobel; S P Goff; M C Nguyen-Huu
Journal:  Science       Date:  1985-05-03       Impact factor: 47.728

8.  Plasmid-encoded hygromycin B resistance: the sequence of hygromycin B phosphotransferase gene and its expression in Escherichia coli and Saccharomyces cerevisiae.

Authors:  L Gritz; J Davies
Journal:  Gene       Date:  1983-11       Impact factor: 3.688

9.  HLA class II regulation and structure. Analysis with HLA-DR3 and HLA-DP point mutants.

Authors:  D Pious; L Dixon; F Levine; T Cotner; R Johnson
Journal:  J Exp Med       Date:  1985-10-01       Impact factor: 14.307

Review 10.  Genetic complexity and expression of human class II histocompatibility antigens.

Authors:  A J Korman; J M Boss; T Spies; R Sorrentino; K Okada; J L Strominger
Journal:  Immunol Rev       Date:  1985-07       Impact factor: 10.983

View more
  13 in total

1.  A new retrovirus packaging cell for gene transfer constructed from amplified long terminal repeat-free chimeric proviral genes.

Authors:  Y Takahara; K Hamada; D E Housman
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

2.  Expression of a swine class II gene in murine bone marrow hematopoietic cells by retroviral-mediated gene transfer.

Authors:  G E Shafer; D W Emery; K Gustafsson; S Germana; W F Anderson; D H Sachs; C LeGuern
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-01       Impact factor: 11.205

3.  A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1.

Authors:  R Longnecker; E Kieff
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

4.  Epstein-Barr virus (EBV) latent membrane protein 2A regulates B-cell receptor-induced apoptosis and EBV reactivation through tyrosine phosphorylation.

Authors:  Makoto Fukuda; Richard Longnecker
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

5.  Induction of transforming growth factor beta 1 resistance by the E1A oncogene requires binding to a specific set of cellular proteins.

Authors:  C Missero; E Filvaroff; G P Dotto
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-15       Impact factor: 11.205

Review 6.  Retrovirus-mediated transfer of MHC class II cDNA into swine bone marrow cells.

Authors:  C LeGuern; H Shimada; D W Emery; S Germana; G E Shafer; D H Sachs
Journal:  J Mol Med (Berl)       Date:  1995-06       Impact factor: 4.599

7.  The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE.

Authors:  X Tong; R Drapkin; R Yalamanchili; G Mosialos; E Kieff
Journal:  Mol Cell Biol       Date:  1995-09       Impact factor: 4.272

8.  Epstein-Barr virus latent membrane protein 2A blocks calcium mobilization in B lymphocytes.

Authors:  C L Miller; R Longnecker; E Kieff
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

9.  Epstein-Barr virus (EBV) recombinants: use of positive selection markers to rescue mutants in EBV-negative B-lymphoma cells.

Authors:  F Wang; A Marchini; E Kieff
Journal:  J Virol       Date:  1991-04       Impact factor: 5.103

10.  Latent membrane protein 2A inhibits transforming growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt pathway.

Authors:  Makoto Fukuda; Richard Longnecker
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.